Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

336 ARTÍCULOS , VIENDO DEL 271 AL 285

Utility of imaging for nutritional intervention studies in Alzheimer's disease

de Wilde MC, Kamphuis PJ, Sijben JW, Scheltens P.

Eur J Pharmacol. 2011 Sep;668 Suppl 1:S59-69. doi: 10.1016/j.ejphar.2011.07.011. Epub 2011 Jul 27.

Neurochemical dementia diagnostics in Alzheimer's disease: where are we now and where are we going?

Lewczuk P, Kornhuber J.

Expert Rev Proteomics. 2011 Aug;8(4):447-58. doi: 10.1586/epr.11.37.

CSF tau, Aβ42, and MHPG differentiate dementia with Lewy bodies from Alzheimer's disease

Aerts MB, Esselink RA, Claassen JA, Abdo WF, Bloem BR, Verbeek MM.

J Alzheimers Dis. 2011;27(2):377-84. doi: 10.3233/JAD-2011-110482.

New diagnostic criteria for Alzheimer's disease

Zetterberg H.

Biomark Med. 2011 Aug;5(4):407-9. doi: 10.2217/bmm.11.46.

Role of amyloid β1-42 and neuroimaging biomarkers in Alzheimer's disease

Lista S, Emanuele E.

Biomark Med. 2011 Aug;5(4):411-3. doi: 10.2217/bmm.11.50.

Role of CSF biomarkers in the diagnosis of prodromal Alzheimer's disease

Parnetti L, Chiasserini D.

Biomark Med. 2011 Aug;5(4):479-84. doi: 10.2217/bmm.11.48.

Brain-derived neurotrophic factor and Alzheimer's disease: physiopathology and beyond

Diniz BS, Teixeira AL.

Neuromolecular Med. 2011 Dec;13(4):217-22. doi: 10.1007/s12017-011-8154-x. Epub 2011 Sep 7.

[Dementia: progress in diagnosis and treatment; Topics; V. Recent topics; 1. Biomarkers for Alzheimer's disease and other dementia]

Tokuda T.

Nihon Naika Gakkai Zasshi. 2011 Aug 10;100(8):2177-86. doi: 10.2169/naika.100.2177.

Alzheimer's disease: implications of the updated diagnostic and research criteria

Reiman EM, McKhann GM, Albert MS, Sperling RA, Petersen RC, Blacker D.

J Clin Psychiatry. 2011 Sep;72(9):1190-6. doi: 10.4088/JCP.10087co1c.

Pyroglutamate amyloid-β (Aβ): a hatchet man in Alzheimer disease

Jawhar S, Wirths O, Bayer TA.

J Biol Chem. 2011 Nov 11;286(45):38825-32. doi: 10.1074/jbc.R111.288308. Epub 2011 Sep 29.

Nuclear medicine diagnostic techniques in the era of pathophysiology-based CSF biomarkers for Alzheimer's disease

Weih M, Degirmenci U, Kreil S, Suttner G, Schmidt D, Kornhuber J, Lewczuk P, Kuwert T.

J Alzheimers Dis. 2011;26 Suppl 3:97-103. doi: 10.3233/JAD-2011-0020.

Disease tracking markers for Alzheimer's disease at the prodromal (MCI) stage

Drago V, Babiloni C, Bartrés-Faz D, Caroli A, Bosch B, Hensch T, Didic M, Klafki HW, Pievani M, Jovicich J, Venturi L, Spitzer P, Vecchio F, Schoenknecht P, Wiltfang J, Redolfi A, Forloni G, Blin O, Irving E, Davis C, Hårdemark HG, Frisoni GB.

J Alzheimers Dis. 2011;26 Suppl 3:159-99. doi: 10.3233/JAD-2011-0043.

Searching for novel biomarkers using high resolution diffusion tensor imaging

Yassa MA.

J Alzheimers Dis. 2011;26 Suppl 3(Suppl 3):297-305. doi: 10.3233/JAD-2011-0005.

Fluorodeoxyglucose positron emission tomography: emerging roles in the evaluation of putative Alzheimer's disease-modifying treatments

Reiman EM; Alzheimer's Disease Biomarkers Working Group for the Alliance for Aging Research.

Neurobiol Aging. 2011 Dec;32 Suppl 1(Suppl 1):S44-7. doi: 10.1016/j.neurobiolaging.2011.09.007. Epub 2011 Oct 7.

Clinical trial methodologies for disease-modifying therapeutic approaches

Aisen PS.

Neurobiol Aging. 2011 Dec;32 Suppl 1(Suppl 1):S64-6. doi: 10.1016/j.neurobiolaging.2011.09.008. Epub 2011 Oct 8.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias